{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=2&state=Oregon", "query": { "state": "Oregon", "city": "Portland", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Portland&page=1&state=Oregon&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T16:02:58.788Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006020", "title": "S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "nelarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 35, "start_date": "2000-07", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 107, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006020" }, { "nct_id": "NCT00040027", "title": "Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a", "type": "DRUG" }, { "name": "placebo + PEGinterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SciClone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2002-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-01-15", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 46, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040027" }, { "nct_id": "NCT03443973", "title": "Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 975, "start_date": "2018-08-22", "completion_date": "2022-11-28", "has_results": true, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 47, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03443973" }, { "nct_id": "NCT03414983", "title": "An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 196, "start_date": "2018-02-20", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414983" }, { "nct_id": "NCT04015141", "title": "A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pediatric Epileptic Syndrome", "Partial-onset Seizures" ], "interventions": [ { "name": "Perampanel Oral Suspension", "type": "DRUG" }, { "name": "Perampanel Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Month to 18 Years" }, "enrollment_count": 100, "start_date": "2019-05-31", "completion_date": "2027-12-23", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT04015141" }, { "nct_id": "NCT05678205", "title": "A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "AB-201", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2023-08-01", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05678205" }, { "nct_id": "NCT01609582", "title": "Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes", "Cardiovascular Disease" ], "interventions": [ { "name": "TAK-875", "type": "DRUG" }, { "name": "TAK-875 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3207, "start_date": "2012-06", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-10-19", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01609582" }, { "nct_id": "NCT01732796", "title": "IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "BI 201335 (Faldaprevir)", "type": "DRUG" }, { "name": "BI 207127", "type": "DRUG" }, { "name": "Faldaprevir (BI 201335)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 470, "start_date": "2012-12", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-04-18", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 24, "location_summary": "Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01732796" }, { "nct_id": "NCT04741646", "title": "Ferric Citrate and Chronic Kidney Disease in Children", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Diseases" ], "interventions": [ { "name": "Ferric Citrate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 160, "start_date": "2022-06-17", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 18, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04741646" }, { "nct_id": "NCT04214262", "title": "Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": "2020-08-13", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-07T16:02:58.788Z", "location_count": 391, "location_summary": "Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214262" } ] }